Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPOCH: Therapeutic drug monitoring with infliximab (Remsima) in pediatric moderate to severe luminal Crohn’s disease
KCT0005190Phase 4Active, not recruiting
- Sponsor
- Celltrion Pharm
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of infliximab in Crohn's disease, sponsored by Celltrion Pharm. Primary endpoints: Mucosal healing and Transmural healing. Started Jul 2017; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on KCT0005190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005190.